Improved Glycemic Control After Long-Term Insulin Pump Use in Pediatric Patients with Type 1 Diabetes
Authors:
- 1 October 2007
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 9 (5) , 421-428
Abstract
Background: There are currently few data available on the long-term use of continuous subcutaneous insulin infusion (CSII) (insulin pump) therapy in children. Methods: Charts from 291 youth with type 1 diabetes (T1D) who were treated with CSII therapy for at least 1 year were reviewed. Data analysis included hemoglobin A1c(HbA1c) values, body mass index (BMI) values, and the occurrence of severe hypoglycemia (SH) or diabetic ketoacidosis (DKA) events. Results: For the 291 patients, the mean age (±SD) for beginning CSII therapy was 13.3 ± 3.7 years. The mean duration of CSII was 3.7 ± 1.9 years (range 1–9 years). The baseline HbA1c value was 8.7 ± 1.0%, compared to 8.2 ± 0.9% after 1 year (P < 0.0001). The most recent value for all patients was 8.3 ± 1.3% (P < 0.0001 compared to the baseline values for the same subjects). There was no advantage in glycemic control in the teen years as a result of initiating CSII in the preteen years compared to the teen years. SH events decreased from 9.06 events per 100 patient-years before CSII therapy to 7.96 events per 100 patient-years while on CSII therapy. The incidence of DKA increased from 1.39 events pre-CSII to 3.98 events per 100 patient-years while on CSII therapy. BMI z-scores showed a nonsignificant increase. Conclusions: The long-term use of CSII in pediatric patients is beneficial in lowering mean HbA1c levels and the number of SH events. However, there was an increase in the number of DKA episodes.Keywords
This publication has 25 references indexed in Scilit:
- Durability of Insulin Pump Use in Pediatric Patients With Type 1 DiabetesDiabetes Care, 2006
- Long‐term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4‐year follow‐upDiabetic Medicine, 2006
- Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? YesDiabetes Care, 2006
- Age-Specific Advantages of Continuous Subcutaneous Insulin Infusion as Compared With Multiple Daily Injections in Pediatric PatientsDiabetes Care, 2006
- Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up ReportPediatrics, 2004
- Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.Diabetes Care, 1999
- Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External PumpsDiabetes Care, 1998
- Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I DiabetesDiabetes Care, 1996
- Pre-meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 DiabetesDiabetic Medicine, 1996
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993